首页> 外文期刊>Annals of nuclear medicine >Lung uptake on I-131 therapy and short-term outcome in patients with lung metastasis from differentiated thyroid cancer
【24h】

Lung uptake on I-131 therapy and short-term outcome in patients with lung metastasis from differentiated thyroid cancer

机译:分化型甲状腺癌肺转移患者对I-131治疗的肺吸收和近期预后

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: It is sometimes difficult to assess I-131 lung uptake at the initial I-131 therapy because of strong artifacts from I-131 uptake in the thyroid bed. The aim of this study was to analyze the lung uptake at the second I-131 therapy for lung metastasis in patients who did not have lung uptake at the initial therapy from differentiated thyroid carcinoma (DTC). Then, we also analyzed the relationship between the initial lung uptake and short-term outcome after I-131 therapies. Methods: This study included 62 DTC patients with lung metastasis. The patients were classified into 2 groups according to the lung uptake at the initial I-131 therapy such as patients with lung uptake (positive uptake group n = 31) and those without lung uptake (negative uptake group n = 31). The lung uptake was analyzed at the second therapy in both groups. The short-term outcome was also analyzed based on the CT findings of lung metastasis size and serum thyroglobulin level between the two groups. Results: The positive uptake group showed positive lung uptake at the second therapy in 23 patients (74 %), whereas none of negative uptake group showed any lung uptake at the second therapy (P < 0.01). The positive uptake group significantly decreased in the size of lung metastasis from the initial therapy to the second therapy (20.0 ± 11.7 to 16.6 ± 9.6 mm, P < 0.01) with further decrease after the second therapy (P < 0.05). The serum thyroglobulin level was also significantly decreased from the initial therapy to the second therapy (4348 ± 7011 to 2931 ± 4484 ng/ml, P < 0.05). In contrast, the negative uptake group significantly increased in the size of lung metastasis from the initial therapy to the second therapy (17.3 ± 12.2 to 19.9 ± 14.3 mm, P < 0.01) with further increase after the second therapy (P < 0.01). Conclusion: No patients without lung uptake at the initial I-131 therapy showed lung uptake at the second therapy, or showed treatment effect. Therefore, second I-131 therapy for these patients with initially negative lung uptake should be considered cautiously.
机译:目的:由于在甲状腺床吸收I-131的强烈伪影,有时在初始I-131治疗时难以评估I-131的肺摄取。这项研究的目的是分析在第二次I-131治疗中从转移性甲状腺癌(DTC)起未接受肺吸收的患者中肺转移的第二次I-131治疗的肺吸收。然后,我们还分析了I-131治疗后初始肺摄取与短期预后之间的关系。方法:本研究包括62例DTC肺转移患者。根据最初的I-131治疗时的肺摄取情况,将患者分为两组,例如有肺摄取的患者(正摄取组n = 31)和无肺摄取的患者(负摄取组n = 31)。两组均在第二种疗法中分析了肺吸收。还根据两组之间肺转移大小和血清甲状腺球蛋白水平的CT结果分析了短期结局。结果:23例患者中,阳性摄入组在第二次治疗时肺部摄取阳性(74%),而阴性摄入组在第二次治疗中均未发现肺部摄取(P <0.01)。从初始治疗到第二次治疗,正摄取组的肺转移灶大小显着减少(20.0±11.7至16.6±9.6 mm,P <0.01),第二次治疗后进一步减少(P <0.05)。从初始治疗到第二种治疗,血清甲状腺球蛋白水平也显着降低(4348±7011至2931±4484 ng / ml,P <0.05)。相反,负摄取组从初始治疗到第二次治疗的肺转移灶明显增加(17.3±12.2至19.9±14.3 mm,P <0.01),而在第二次治疗后进一步增加(P <0.01)。结论:在最初的I-131治疗中没有肺部吸收的患者在第二次治疗中没有出现肺部吸收或显示出治疗效果。因此,应谨慎考虑对最初肺吸收为负的患者进行第二次I-131治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号